Requiring an amyloid-β_1-42 biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials

Lon S. Schneider, Richard E. Kennedy and Gary R. Cutter

Alzheimer`s & Dementia 6 ( 5 ): 367 - 377 , 2010